Key facts
- It has raised $210K; the latest was Angel (individual) ($210K) in Feb 2026.
- Notable investors include U.S. Department of Health and Human Services.
- Verra Therapeutics has filed 1 Form D with the SEC, most recently Feb 2026 ($205K sold to 6 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Verra Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Verra Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Verra Therapeutics
Operator of a biotechnology research and drug development company intended to transform the treatment of protease-driven inflammatory and fibrotic diseases. The company offers a native peptide inhibitor platform, selective small protein drug candidates targeting membrane-bound regulatory proteases, and subcutaneous and inhaled delivery approaches, enabling patients with chronic obstructive pulmonary disease to receive targeted therapies that preserve beneficial protein functions while reducing harmful inflammatory and tissue remodeling activity.
- Sector
- Healthcare
- HQ
- Lansing, NY, United States
- Founded
- 2017
- Website
- verratherapeutics.com/
- Ownership
- Privately Held (backing)
Verra Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Verra Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Verra Therapeutics in its N-PORT filings yet. We sweep new filings monthly.